UNSPSC 51434907: Amlodipine/hydrochlorothiazide/olmesartan

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434907 Amlodipine/hydrochlorothiazide/olmesartan is a Commodity code that covers specific combination antihypertensive medications, but recent state and local procurement activity shows the code is being used to solicit a broader range of pharmaceutical supplies — including emergency medications, generic multi-source pharmaceuticals, and over-the-counter products — rather than the single drug class the code name specifies. State and local purchasing departments, health agencies, emergency services, and cooperative purchasing alliances are using this and related pharmaceutical codes to procure medications for emergency medical services, state health benefit programs, and institutional healthcare distribution networks. The actual buying focuses on branded or generic pharmaceutical products with specific National Drug Codes (NDCs), often bundled with supply-chain requirements including wholesaler relationships, pricing formats, Good Manufacturing Practice certifications, and Drug Supply Chain Security Act compliance.

Recent activity spans Florida, Minnesota, and Texas. The City of Tampa's Purchasing Department issued an IFB (Solicitation 26P00188) in April 2026 for Advanced Life Support Medications including Labetalol, Epinephrine, Adenosine, and Diltiazem for Tampa Fire Rescue, with a response date of April 8, 2026 and an estimated contract value of $40,000.00, featuring a Small Local Business Enterprise sheltered market designation with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) due March 26, 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities, including Oregon, with weighted evaluation emphasizing price competitiveness at 75 percent and requiring vendor relationships with authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs for the state's pharmacy benefit program, signaling early-stage procurement planning for future formal solicitations.